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Abstract. Alanine/glyoxylate aminotransferase 1 
(AGT) is peroxisomal in most normal humans, but in 
some patients with the hereditary disease primary hy- 
peroxaluria type 1 (PH1), AGT is mislocalized to the 
mitochondria. In an attempt to identify the sequences 
in AGT that mediate its targeting to peroxisomes, and 
to determine the mechanism by which AGT is mistar- 
geted in PH1, we have studied the intracellular com- 
partmentalization of various normal and mutant AGT 
polypeptides in normal human fibroblasts and cell lines 
with selective deficiencies of peroxisomal protein im- 
port, using immunofluorescence microscopy after intra- 
nuclear microinjection of AGT expression plasmids. 
The results show that AGT is imported into peroxi- 
somes via the peroxisomal targeting sequence type 1 
(PTS1) translocation pathway. Although the COOH- 
terminal KKL of human AGT was shown to be neces- 
sary for its peroxisomal import, this tripeptide was un- 
able to direct the peroxisomal import of the bona fide 
peroxisomal protein firefy luciferase or the reporter 
protein bacterial chloramphenicol acetyltransferase. 
An ill-defined region immediately upstream of the 
COOH-terminal KKL was also found to be necessary 
for the peroxisomal import of AGT, but again this re- 
gion was found to be insufficient to direct the peroxiso- 
mal import of chloramphenicol acetyltransferase. Sub- 
stitution of the COOH-terminal KKL of human AGT 
by the COOH-terminal tripeptides found in the AGTs 
of other mammalian species (SQL, NKL), the proto- 
typical PTS1 (SKL), or the glycosomal PTS1 (SSL) also 
allowed peroxisomal targeting, showing that the allow- 
able PTS1 motif in AGT is considerably more degener- 
ate than, or at least very different from, that acceptable 
in luciferase. AGT possessing the two amino acid sub- 
stitutions responsible for its mistargeting in PH1 (i.e., 
Proll---~Leu and Glyl70---~Arg)  was targeted mainly to 
the mitochondria. However, AGTs possessing each 
amino acid substitution on its own were targeted 
normally to the peroxisomes. This suggests that 
Glyl70~Arg-mediated increased functional efficiency 
of the otherwise weak mitochondrial targeting se- 
quence (generated by the Proll---~Leu polymorphism) 
is not due to interference with the peroxisomal target- 
ing or import of AGT. 
U 
NDER the  putative  influence  of dietary  selection 
pressure,  the  intracellular  compartmentalization 
of alanine/glyoxylate aminotransferase 1 (AGT)  1 
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has changed on many occasions during  the evolution of 
mammals (7, 10). In some mammals, such as rabbits and 
most humans,  AGT is exclusively peroxisomal (3, 7, 27, 
45);  in  other  mammals,  such  as cats  and  dogs, AGT is 
mainly mitochondrial (7, 31); in yet other mammals, such 
as marmosets and  rats,  AGT is more evenly distributed 
between both organelles (7, 26, 28, 44). This variable dual 
compartmentalization  of AGT  is  related  to  its  putative 
targeting sequence; PH1, primary hyperoxaluria type 1; PTS, peroxisomal 
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peroxisomes) and gluconeogenesis (in the mitochondria) 
(7, 10).  The functional importance of correct AGT com- 
partmentalization is  vividly demonstrated by the  human 
autosomal recessive disorder primary hyperoxaluria type 1 
(PH1) (5). In some patients, disease is caused by an unpar- 
alleled inter-organelle mistargeting phenomenon in which 
AGT is  aberrantly targeted and imported into the mito- 
chondria (6), where it is unable to fulfil its proper meta- 
bolic role of glyoxylate detoxification even though it re- 
mains catalytically active. 
In all animals studied so far (i.e., human, marmoset, rab- 
bit, rat, cat), AGT is encoded by a single gene (21, 23, 29, 
36, 37). Therefore, this gene must have the potential to en- 
code mitochondrial and/or peroxisomal targeting sequences, 
depending on the particular species. Where present (i.e. in 
the marmoset, rat,  and cat), the cleavable NH2-terminal 
mitochondrial  targeting  sequence  (MTS)  of  AGT  has 
been clearly identified (21, 30, 37). However, the location 
and nature of the peroxisomal targeting sequence (PTS) of 
AGT has not been determined. 
Acquisition and loss of the ability to target AGT to a 
particular organelle during mammalian evolution is due to 
a  combination  of the  use  of multiple  transcription  and 
translation  initiation sites,  so that the  MTS is  either in- 
cluded or excluded from the open reading frame (21, 29, 
37, 42). The mistargeting of AGT from the peroxisomes to 
the mitochondria in some PH1 patients is due to the com- 
bined effects of a  normally occurring Proll---~Leu poly- 
morphism  and a  PHi-specific Glyl70---~Arg point muta- 
tion (or possibly a Phe152---~Ile mutation in a few patients) 
(8, 34, 35). The Proll--~Leu polymorphism leads to the gen- 
eration of a novel, functionally rather weak, noncleavable, 
NH2-terminal MTS, that is not homologous with the an- 
cestral MTS (i.e., that found in the marmoset, rat, and cat). 
It has been suggested previously that the Gly170---~Arg and 
Phe152---)Ile mutations, which occur within an internal very 
highly conserved region of 58 amino acids, might increase 
the  functional  efficiency of  the  otherwise  rather  weak 
MTS by inhibiting the  peroxisomal targeting  and/or im- 
port of AGT (34, 35). 
In mammals, two types of PTS have been identified so 
far (39). The first PTS characterized (PTS1) consists of a 
simple  COOH-terminal  tripeptide  with  a  consensus  se- 
quence of S(A,C)-K(R,H)-L(M) (15, 41). This PTS1 motif, 
which is not cleaved after import, is found in many mam- 
malian  and nonmammalian peroxisomal matrix proteins. 
SKL has been found not only to be necessary for the im- 
port of the model peroxisomal protein firefly luciferase, 
but also to be sufficient to target otherwise cytosolic pro- 
teins  (e.g.,  bacterial  chloramphenicol  acetyltransferase, 
CAT) to mammalian peroxisomes when attached to their 
COOH termini (14, 15). 
The only other well-characterized PTS in mammals  is 
the PTS2, which has so far only been clearly identified in 
3-ketoacyl-CoA-thiolase. It consists of a  cleavable NH2- 
terminal sequence of 26 or 36 amino acids depending on 
species (32, 40) with a putative consensus motif of xn-RL- 
xs-H/QL-xn, the R and the H being residues -24 and -17, 
respectively, relative to the presequence cleavage site (11). 
The PTS  of AGT has  yet to  be  identified.  Although 
there are a number of similarities between the COOH ter- 
mini of mammalian AGTs (i.e., KKL, SQL, NKL) and rec- 
ognized PTSls, and between the NH2 terminus of at least 
human AGT (i.e., x4-KL-xs-KA-xn) and recognized PTS2s, 
neither fulfils the requirements of either a PTS1 or PTS2 
mammalian consensus sequence. The identification of two 
mutations  (Glyl70---~Arg  and  Phe152---~Ile)  in  a  highly 
conserved  internal  region  of  AGT  in  PH1  patients  in 
whom AGT is mistargeted to the mitochondria has raised 
the possibility that AGT might contain a  novel, internal 
PTS (4). 
In the present study, we have identified the peroxisomal 
import pathway of AGT and  partially characterized the 
nature of its PTS. In addition, we have further examined 
the role of the Glyl70---~Arg mutation in AGT mistarget- 
ing. Our results show that AGT is imported via the PTS1 
protein  translocation  machinery. However, the  COOH- 
terminal tripeptide of AGT is shown to be both more con- 
text-specific and yet more degenerate than previously found 
for mammalian PTSls. In addition, we show that, contrary 
to  previous  suggestions,  the  PHi-specific  Glyl70---~Arg 
mutation does not interfere with the peroxisomal targeting 
or import of AGT. 
Materials and Methods 
A GT and CAT Expression Plasmids 
The vector used for the expression of mammalian AGT  and bacterial 
CAT and their various constructs was derived from pHYK (33),  which 
was a kind gift from H. R. B. Pelham (MRC Laboratory of Molecular Bi- 
ology, Cambridge, UK). pHYK contained the adenovirus major late pro- 
moter, the chick lysozyme-coding sequence followed by a c-myc epitope 
and the peptide SEKDEL, the herpes virus tk gene polyadenylation site 
and the SV-40 origin of replication (see Fig. 1 A). For the AGT and CAT 
expression studies, the insert (i.e., lysozyme, the c-myc epitope and part of 
the SEKDEL peptide) between the HindIII  and BamHI  sites was re- 
placed by the gene construct of interest (see below). 
Normal and Mutant PHI Human AGT Clones and 
Their Derivatives 
The eight plasmids containing normal and mutant PH1 human AGT con- 
structs (pAGT-pgi, pAGT-lgi, pAGT-lri, pAGT-lgm, pAGT-lrm, pAGT- 
pri, pAGT-prm, and pAGT-pgm) (see Table I) were made by cutting out 
the inserts of the equivalent clones in pBluescriptKS+ (i.e., pPGI, pLGI, 
pLRI, pLGM, pLRM, pPRI, pPRM, and pPGM, respectively) (34)  with 
HindIII  and  BamHI  and  cloning  them  into  HindIII/BamHI-digested 
pHYK (see Fig. 1 A). 
Mutagenesis of the 3' Terminus of  AGT 
Human AGT cDNA possesses a single ApaI site (118 bp from the end of 
the coding region) as does the polylinker of pBluescriptIIKS+. To help 
with  the  COOH-terminal  PCR  mutagenesis strategy  (see  below), the 
ApaI site in the pBluescriptIIKS+ was deleted by digesting with Apal, 
blunt-ending with T 4 DNA polymerase and religating with T4 DNA ligase 
to produce pBS  ApaI-. The insert from pPGI (see above) was cut out with 
HindIII  and  BamHI  and  was  recloned  into  HindIII/BamHI-digested 
pBS  ApaI" to produce pBSApaI'PGI. 
pAGT~-SKL, pAGT~-SQL, pAGT~-NKL, pAGT~-SSL, pAGT"-SEL, 
pAGT~-DEL, and pAGT~-LLL (see Table I) were made by amplifying 
the 3' end of the insert of pPGI (see above) by PCR, using the primer 
pairs P9/P2,  P9/P5,  P9/P4,  P9/P3,  P9/P6,  P9/PS,  and P9/P7,  respectively 
(see Table II). The PCR products were digested with ApaI (that cuts 324 
bp downstream of pc)) and BamHI  (cuts within the reverse strand mu- 
tagenic primers) and cloned into ApaI/BamHI-digested pBSApaLPGI. To 
check for PCR incorporation errors, the sequences of the inserts were 
checked between the ApaI and BamHI sites. The inserts were cut out with 
HindIII and BamHI and recloned into HindIII/BamHI-digested pHYK to 
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Figure 1.  Partial structure of 
the  pHYK  expression plas- 
mid  (A)  and  PCR  strategy 
for generation of AGT con- 
structs (B).  Restriction sites: 
H,  HindlII;  B,  BamHI  (B*, 
BamHI  sites  introduced  by 
-strand  primers);  A,  ApaI 
(A',  ApaI  site  deleted  in 
pBSApaI-);  As,  AspI;  Ns, 
NsiI; X,  XbaI;  R, EcoRI; S, 
SmaI; SI, SacI; SII, SaclI; Nc, 
NcoI. P1-8, P12, P13, and P17 
are -strand primers, and P9, 
P15,  and  P16  are  (+)strand 
primers described in Table II. 
produce pAGT~-SKL, pAGT~-SQL, pAG'I~-NKL, pAGT~-SSL, pAGT  ~- 
SEL, pAGT~-DEL, and pAGT~-LLL. 
pAGT~-A1 was made as follows. The 3' portion of the insert of pPGI 
(see above) was amplified by PCR using the primer pair P9/P1 (see Table 
II). pPGI and the P9/PI PCR product were digested separately with Apal, 
mixed together and ligated with T4 DNA ligase. The ligated mixture was 
then double digested with HindlII and BamHl and the required fragment 
of ~1.3 kb was gel purified. This was then ligated to the gel-purified large 
HindlII/BamHI fragment of pBS  ApaI- to produce pBSApaX-AGT~-A1.  The 
sequence of the  PCR  amplified  portion  (i.e.,  between the  ApaI  and 
BamHI sites) was checked for artefacts  and then the insert was cut out 
with  HindlII  and  BamHI  and  recloned into  HindlII/BamHI-digested 
pHYK to produce pBSApa~-AGT~-z~I. 
pAGT~-A1 was made by digesting pLGM (see above) with NcoI and 
Table 1. Description of the AGT, CAT, and Luciferase Expression Plasmids Used in the Present Study 
Plasmid  Synonym  Description 
pAGT-pgi 
pAGT-lgi 
pAGT- 1  ri 
pAGT-lgm 
pAGT-lrm 
pAGT-pri 
pAGT-prm 
pAGT-pgm 
pAGT~-SKL 
pAG'W-SQL 
pAG'W-NKL 
pAG'W-SSL 
pAGT~-SEL 
pAGT~-DEL 
pAGT~-LLL 
pAG'W-A  1 
pAGT~-A 1 
pAGT~-A2 
pAGT~-A3 
pFFL-SKL 
pFFL-KKL 
pCAT 
pCAT-SKL 
pCAT-KKL 
pCAT+AGT13 
pCAT + AGT47 
pCAT + AGT47-SKL 
pAGT  ~ 
pAGTa 
pAGT  v 
Normal human AGT encoded by the major allele 
pAGT '~ containing a Pro 11---~Leu substitution 
pAGT '~ containing Pro 11---->Leu and Gly 170--*Arg  substitutions 
Normal human AGT encoded by the minor allele, contalningPro 11--~Leu and Ile340---~Met  substitutions 
Mutant human AGT encoded by the PHI mistargeting allele, containing Prol 1-4Leu, Glyl70--->Arg  and 
Ile340--~Met substitutions 
pAGT ~ containing a Gly170---~Arg  substitution 
pAGT ~ containing Gly 170--->Arg and Ile 340--)Met substitutions 
pAGT ~ containing a Ile340---~Met  substitution 
COOH-terminal KKL of pAGT  ~ substituted by SKL 
COOH-terminal KKL of pAGT  ~ substituted by SQL 
COOH-terminal KKL of pAGT  ~ substituted by NKL 
COOH-terminal KKL of pAGT  ~ substituted by SSL 
COOH-terminal KKL of pAGT  ~ substituted by SEL 
COOH-terminal KKL of pAGT  ~ substituted by DEL 
COOH-terminal KKL of pAGT  ~ substituted by LLL 
COOH-terminal KKL of pAGT  '~ deleted 
COOH-terminal KKL of pAGT~ deleted 
10 amino acids from -  13 to -4, inclusive, deleted from pAGT% the COOH-terminal KKL being kept intact 
44 amino acids from -47 to -4, inclusive, deleted from pAGT  ~, the COOH-terminal KKL being kept intact 
Normal firefly luciferase 
COOH-terminal SKL of pFFL-SKL substituted by KKL 
Bacterial chloramphenicol acetyltransferase 
SKL added to COOH terminus of pCAT 
KKL added to COOH terminus of pCAT 
COOH-terminal 13 amino acids of AGT added to the COOH terminus of pCAT 
COOH-terminal 47 amino acids of AGT added to the COOH terminus of pCAT 
COOH-terminal KKL of pCAT+AGT47  substituted by SKL 
The AGT and CAT plasmids  are all based on the parent mammalian  expression  vector pHYK (see Materials and Methods). The equivalent pBluescriptlIKS+ plas- 
mids are referred to as appropriate in the text. COOH-terminal amino acid substitutions  are indicated in upper case (e.g.,  SKL),  whereas internal substitutions  are in- 
dicated in lower case (e.g., lrm). The luciferase  expression  plasmids  are described in the text. 
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Primer  Sequence  Maps to:*  Strand  Constructs 
P 1  5'-AAGAGCTCGGATCCTCACTTGGGGCAGTGCTG-3'  -  13 to -  27  (-) 
P2  5 '-CATCATGGATCCTCACAGCTTCGACTTGGGGCAG-3'  -  1 to -  22  (-) 
P3  5'-CATCATGGATCCTCACAGGCTCGACTTGGGGCAG-3'  -  1 to -22  (-) 
P4  5'-CATCATGGATCCTCACAGCTTGTTCTTGGGGCAG-3'  -  1 to - 22  (-) 
P5  5'-CATCATGGATCCTCACAGCTGCGABCTTGGGGCAG-3'  -  1 to - 22  (-) 
P6  5'-CATCATGGATCCTCACAGCTC=CGA_  CTTGGGGCAG-3'  -  1 to - 22  (-) 
P7  5'-CATCATGGATCCTCACAGCAGCAG____CTTGGGGCAG-3'  -  1 to -  22  (-) 
P8  5'-CATCATGGATCCTCACAGCTCGTC__CTTGGGGCAG-3'  -  1 to - 22  (-) 
P9  5'-CTTCTCCTTCTCCCTGGACA-3'  -469 to -450  (+) 
P 10  5'-CATCATGGATCCTTATAATTTTGACGCCC-3'  + 9 to -  8  (-) 
P 11  5'-CATCATGGATCCTTATAATTTTTTCGCCC-3 '  + 9 to -  8  (-) 
P12  5'-CGTCGTGGATCCTCACAGCTTCTFGGCCTCCGTCACGCG-3'  -43 to -57  (-) 
P 13  5 '-CGTCGTGGATCCTCACAGCTTCTTAATGTCGAAGTGGTC-3'  -  145 to -  159  ( -  ) 
P14  5'-CATCATGGATCCCATGCATGCGCCCCGCCCTGCCACTC-3'  -4 to -  21  (-) 
P 15  5'-CTGAGGGCGGCCCTGCAGC-3'  - 42 to -  24  (+) 
PI 6  5'-GAGATCATGGGTGGCCTTG-3'  -  144 to -  126  (+) 
P17  5'-GTTTGCTCCGGATCCCTCAG-3'  +72 to +53  (-) 
pAGT~-A 1 
pAGT~-SKL 
pAGT~-SSL 
pAGT~-NKL 
pAGT~-SQL 
pAGT~-SEL 
pAGT~-LLL 
pAGT~-DEL 
All pAGT constructs 
pCAT-SKL 
pCAT-KKL 
pAGT~-A2 
pAGT'I-A3 
pFCAT 
pCAT+AGT(13) 
pCAT+AGT(47) 
pCAT+ AGT(13) 
P1-8 are -  strand  PCR primers  used for modifying  the COOH  terminus  of AGT. P1, P2, P3, P4, P5, P6, P7, and P8 were used to generate pAGq~-A  1, pAGT~-SKL,  pAGT~-SSL, 
pAGT~-NKL, pAGT~-SQL,  pAGT~-SEL, pAGT~-LLL, and pAGT~-DEL, respectively. P12 and PI3 are -  strand primers used for making the internal AGT deletion constructs 
pAGT~-A2 and pAGT~-A3. P9 is the + strand primer used in combination  with PI-8, P12, and P13. P10 and P11 are -  strand PCR primers used for making  the COOH-terminal 
pCAT-SKL and pCAT-KKL  fusions, respectively. P14 is a -  strand primer used to make the general purpose CAT fusion vector pFCAT. PI0, P11, and PI4 were used in con- 
junction with the M13 reverse sequencing  primer as the + strand primer. P15 and P16 are +  strand primers used with the -  strand primers P17 and M13 universal  sequencing 
primer, respectively, to make the CAT-AGT  fusions pCAT+AGT13 and pCAT+AGT47. Bold type indicates the parts of the primers thal hybridise to the starting AGT or CAT 
templates, the nonbold  type indicating the non-hybridising  5' tails. The single underlines indicate the BamHl (and SphI in the case of P14) restriction sites used for cloning. The 
doable underlines indicate the mutant bases. *, The nucleotides to which the primers (hybridizing sequences)  map are numbered  from the last base of the original stop codon (i.e. 
base -  1). P1-9, PI2, P13, and P15-17 map to AGT sequences  and P10, P11, and P14 map to CAT sequences. P17 maps to the 3'UTR of AGT, whereas  all other primers (except 
the M13 primers)  map to coding regions. 
Apal and cloning the 1.2-kb fragment into NcoI/ApaI-digested pBS  Apal- 
AGT~-A1. This was then digested with HindlII and BamHI and the insert 
cloned into HindlII/BamHI-digested pHYK. 
Two AGT constructs, pAG'F'-A2 and pAGT~-A3, in which the 10 or 44 
amino acids immediately upstream of the COOH-terminal KKL (i.e., resi- 
dues -13 to -4 or -47 to -4 inclusive)  were deleted (see Table I), were 
made as follows, pPGI was amplified by PCR using primer pairs P9/P12 or 
P9/P13, respectively (see Table II). The products were cut with AspI (cuts 
270 bp downstream of P9, see Fig. 1 B) and BamHI (cuts in the reverse- 
strand primers), and cloned into AspI/BamHI-digested pBSApaVPGI. Af- 
ter checking for possible PCR errors between the AspI and BamHI sites, 
the HindlIl/BamHI fragments of these constructs were then cloned into 
HindlII/BamHI-digested pHYK to produce pAGT~-A2 and pAGT~-A3. 
Generation of the COOH-terminal CAT Fusions 
The insert of pBLCAT2 (20), comprising the coding region of the CAT 
gene together with the T intron and polyadenylation signal,  was cut out 
with Bglll  and  SmaI. The BgllI site  was blunt-ended with DNA poly- 
merase I (Klenow fragment) and the product was cloned into the EcoRV 
site  of pBfuescriptlIKS+.  A  positively  orientated  clone  was  selected 
(pBSCAT) and the HindlII/BamHI-digested insert was cloned into the 
HindlII and BamHl sites of pHYK to make pCAT. pCAT-SKL (see Ta- 
ble I) was made by amplifying the insert of pBSCAT by PCR, using the 
M13 reverse sequencing primer (+ strand) and the mutagenic primer P10 
(- strand) (Table II). The PCR product was cut with NcoI (cuts within the 
CAT coding region) and BamHI (cuts within P10)  and the NcoI/BamHI 
fragment was cloned back into pBSCAT, replacing the native fragment, to 
produce pBSCAT-SKL. After checking for PCR errors between the NcoI 
and  BamHI sites,  the  HindlII/BamHI fragment of pBSCAT-SKL was 
cloned  into  HindlII/BamHI-digested  pHYK  to  produce  pCAT-SKL. 
pCAT-KKL (see Table I) was produced similarly,  except that the PCR 
template was pBSCAT-SKL and the mutagenic primer was Pll (Table II). 
To simplify  the construction of larger CAT-AGT fusions, a  general 
purpose CAT-fusion vector pFCAT was made as follows,  pBSCAT was 
amplified by PCR using primer P14 (Table If) and the M13  reverse se- 
quencing primer. P14 places a  SphI site across the final  codon of CAT 
that, after digestion and incubation with T4 DNA polymerase, creates a 
blunt end immediately after the final codon. The PCR product was di- 
gested with NcoI (cuts 142 bp upstream of the end of the coding region) 
and BamHI (cuts in P14 downstream of the SphI site) and cloned back 
into pBSCAT digested with NcoI and BamHt (cuts in the polylinker). The 
sequence between the NcoI and BamHI sites was checked for PCR arte- 
facts. 
Two COOH-terminal CAT-fusions, pCAT+AGT13 and pCAT+AGT47 
(see Table I), which included  the last 13 or 47 amino acids of AGT, respec- 
tively,  were made as follows,  pPGI was amplified by PCR using primer 
pairs P15/P17 or P16/M13 universal primer, respectively  (see Table II). The 
products  were  blunt-ended  with  T4  DNA  polymerase,  digested  with 
BamHI (cuts downstream of the AGT stop codon in P17 when the latter 
was used or in the polylinker when the M13 primer was used), and cloned 
into pFCAT, which had previously been digested with SphI, blunt-ended 
with T4 DNA polymerase, and then digested with BamHI. After checking 
for possible PCR artefacts between the COOH terminus of CAT and the 
AGT stop codon, the resulting in-frame fusions were digested  with HindIII 
and BamHI and cloned into HindlII/BamHl-digested pHYK to produce 
pCAT+AGT13 and pCAT+AGT47, pCAT+AGT47-SKL was made by 
replacing the ApaI/BamHI fragment of pCAT+AGT47 with the equiva- 
lent fragment of pAGT~-SKL. 
Firefly Luciferase Expression Plasmids and 
Mutagenesis of the 3' Terminus of Firefly Luciferase 
Construction of the plasmid expressing normal firefly  luciferase  (pFFL- 
SKL) has been described previously (referred to as pCDNALuc in refer- 
ence 24). pFFL-KKL was made by amplifying by PCR the insert of pFFL- 
SKL using the T  7 (+strand) primer and the COOH-terminal (- strand) 
mutagenic  primer  5'-TTTTCTGCAGTTACAATTTTFTCTTTCCGC- 
CCTTCTTGGCC-3'  that contained a  PstI restriction site (underlined). 
The resulting 1.8-kb  PCR fragment was digested with PstI and BamHI 
(cuts in the 5' polylinker) and cloned into the BamHI/PstI-digested parent 
expression vector pCDNA (24). The 1.5-kb BamHI/EcoRV fragment was 
replaced  by  the  corresponding fragment  from pFFL-SKL and  the  se- 
quence  of  the  remaining  0.3-kb  PCR-amplified  portion  (between  the 
EcoRV and PstI sites) was checked for artefacts. 
Cell Culture and Human Fibroblast Cell Lines 
Primary skin fibroblasts were used for microinjection experiments and 
were  derived  either  from  control  subjects  (cell  lines  85AD5035F, 
HENG90AD, and MC98) or from two patients suffering from peroxisome 
assembly disorders: the PTS1- line was derived from a neonatal adreno- 
leukodystrophy patient (cell line AAL85AD) and the PTS2- line was de- 
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(cell line MCHE85AD).  These cell lines have been characterized  in detail 
elsewhere (24). Cells were grown in a 1:1 mixture of Dulbecco's modified 
Eagle's medium and Ham's F10 (GIBCO BRL, Glasgow, UK) supple- 
mented with 10% fetal calf serum (GIBCO BRL) under 5% CO2. Cells 
were split 1:4 on reaching confluence and were not used above passage 30. 
Figure  2.  Intracellular  local- 
ization  of naturally  occurring 
normal and PH1 AGTs in nor- 
mal  human  fibroblasts.  Dou- 
ble-label  immunofluorescence 
of AGT  ~ (A), AGT~  (C), and 
AGT  v  (E)  and  peroxisomal 
thiolase (B, D, and F, respec- 
tively).  Double-labeling  pat- 
terns  in  normal  human  fibro- 
blasts  of  an  endogenous 
mitochondrial  protein  (cyto- 
chrome  oxidase  [G])  and  a 
peroxisomal  protein  (thiolase 
[HI)  are  shown  for  com- 
parison. 
Microinjection 
24 h before microinjection, the cells were plated onto microinjection grids 
or cover slips. The needles were made using a PB-7 micropipette puller 
(Narishage Co., Tokyo, Japan) and DNA was injected in reverse PBS (4 
mM Na2HPO4, 1 mM KH2PO4, 140 mM KCI, pH 7.3). DNA was injected 
Motley et al. PTS1 ofAlanine/Glyoxylate  Aminotransferase  99 at a concentration of 0.05 mg/ml, equivalent to ~50 molecules per injec- 
tion. Except where indicated in the text, 18 h after microinjection, the cells 
were processed for immunofluorescence microscopy. 
Immunofluorescence Microscopy 
The cells were washed in PBS and fixed in freshly prepared 4% (wt/vol) 
paraformaldehyde/0.1% Triton X-100  (pH 7.5) for 20 rain at room tem- 
perature.  For differential  permeabilization,  the  cells  were fixed in 4% 
paraformaldehyde in PBS for 20 min and treated with 25 i~g/ml digitonin 
in PBS (to permeabilize the plasma membrane only) or 25 ~g/ml digitonin 
in PBS, containing 0.1%  Triton X-100  (to permeabilize both the plasma 
membrane and the peroxisomal membrane). Free aldehyde groups were 
blocked by incubating for 10 min in 0.1 M NH4CI in PBS. The cells were 
then processed for single-  or double-label indirect immunofluorescence 
using the following antibodies: monoclonal mouse anti-rat thiolase (3G4) 
(17); monoclonal mouse anti-human catalase (43); polyclonal guinea pig 
anti-rat catalase (kind gift from Dr. S.Yokota, Yamanashi Medical  Col- 
lege, Japan); polyclonal guinea pig anti-firefly luciferase (18); polyclonal 
rabbit anti-bovine cytochrome oxidase (kind gift from Dr. C. van den Bo- 
gert, E. C. Slater Institute, Amsterdam); polyclonal rabbit anti-CAT; and 
polyclonal rabbit anti-human AGT. For the double-labeling experiments, 
AGT was visualized  with FITC- or TRITC-conjugated donkey anti-rabbit 
IgG (Jackson ImmunoResearch Laboratories, West Grove, PA); firefly 
luciferase was visualized  using FITC-conjugated goat anti-guinea pig IgG 
(Jackson  ImmunoResearch  Laboratories);  CAT  was  visualized  with 
FITC-conjugated goat anti-rabbit IgG (Sigma Chemical Co., Poole, UK); 
and thiolase and catalase were visualized  using cy3-conjugated goat anti- 
mouse  IgG  (Jackson  ImmunoResearch Laboratories)  or  biotinylated 
sheep anti-mouse IgG (Amersham International, Amersham, UK) fol- 
lowed  by  streptavidin,labeled  FITC  or  TRITC  (Amersham  Interna- 
tional). In the CAT double-labeling experiments, catalase was visualized 
with biotinylated goat anti-guinea pig IgG (Vector Laboratories, Peter- 
borough, UK) followed by avidin-labeled Texas Red (Vector Laborato- 
ries).  For single  labeling,  FITC-conjugated donkey anti-rabbit IgG was 
used. The incubations were all performed at room temperature for 45 min 
in PBS containing 10 mg/ml BSA (to reduce nonspecific binding). After 
each incubation the cells were washed extensively in PBS.  The injection 
grids/cover slips were mounted on cover slips/slides, respectively,  in either 
carbonate-buffered  glycerol  containing  p-phenylenediamine  or  Mowiol 
(Harlow Chemical  Co.  Ltd.,  Harlow, UK) containing DABCO (Sigma 
Chemical Co.). In most experiments, the fluorescent staining pattern was 
viewed in an Olympus IMT2 (RFL) fluorescence microscope, using an 
IMT2DMB filter for excitation of the FITC signal, and an IMT2-DMG fil- 
ter for excitation of the TRITC signal.  FITC fluorescence was visualized 
in combination with the G520  barrier filter and TRITC fluorescence in 
combination with the  R610  barrier filter.  Fluorescent images were re- 
corded on Kodak TMAX 400 ASA B/W film. In the experiments involving 
the expression of CAT-fusions and internal AGT deletions, the fluorescent 
staining pattern was viewed in a Biorad MRC1000  confocal laser-scanning 
microscope,  using  OG515  (fluorescein)  and  585EFLP  (tetramethyl- 
rhodamine/Texas Red) filters. The captured images were manipulated us- 
ing Adobe Photoshop software installed  on a Macintosh computer, and re- 
corded onto Kodak TMAX 100 ASA B/W film  using a  Sapphire slide 
recorder (Management Graphics Inc., Minneapolis, MN). 
Results 
The subcellular distribution of various naturally occurring 
and artificial AGT derivatives was determined by immu- 
nofluorescence microscopy 18 h after the intranuclear mi- 
croinjection of AGT expression plasmids. This procedure 
allowed prolonged expression of the gene of interest, and 
gave the cells time to recover from the trauma of microin- 
jection before AGT localization was determined. 
Compartmentalization of Normal and Mutant PHI 
A GT in Normal Human Fibroblasts 
Normal human AGTs encoded by both the more common 
major and less common minor alleles (AGT  ~ and AGT~, 
respectively)  were  imported  into  a  particulate  compart- 
ment which  labeled for the peroxisomal marker enzyme 
Table IlL Summary of the Results for the lntracellular 
Compartmentalization of Various AGT, Luciferase, and CAT 
Constructs in Human Fibroblasts Compared with the 
Distribution of the Endogenous Gene Products (AGT only) in 
Human Livers 
Subcellnlar distribution 
Liver 
Fibroblasts  Peroxisome 
Normal  assembly 
Plasmid  Normal  PTS1-  PTS2-  or PH1  disorders 
pAGT-pgi (pAGT  ~)  P  C  P  P  C 
pAGT-lgi  P  .... 
pAGT-lri  M +  P  .... 
pAGT-lgm (pAGT  I~)  P  C  -  M +  P  M +  C 
pAGT-lrm (pAGT  v)  M +  P  M  -  M  +  e  - 
pAGT-pri  P  C  -  -  - 
pAGT-prm  P  .... 
pAGT-pgm  P  .... 
pAGT~-SKL  P  .... 
pAG'W-SQL  P  .... 
pAGT~-NKL  P  .... 
pAGT~-SSL  P  .... 
pAGT~-SEL  C  .... 
pAGT~-DEL  C  .... 
pAGT~-LLL  C  .... 
pAGT~-A 1  C  C  -  -  - 
pAGT~-A1  C  C  -  -  - 
pAGT~-A2  C  -  -  - 
pAGT~-A3  C  .... 
pFFL-SKL  P  C  P  -  - 
pFFL-KKL  C  .... 
pCAT  C  .... 
pCAT-SKL  P  .... 
pCAT-KKL  C  .... 
pCAT+AGT13  C  .... 
pCAT + AGT47  C  .... 
pCAT  + AGT47-S KL  P  .... 
The normal, PTS t- and PTS2- fibroblasts (24) are described in the text. The subcel- 
lular distribution in normal liver (3, 34) and peroxisome-assembly  disorder liver (9) 
applies to AGT  ~ and AGT  ~, while that for PHl liver (6) applies only to AGT  v. The 
subcellular distribution is defined as M (mitochondrial), P (peroxisomal),  or C (cyto- 
solic), tn the cases of endogenous AGT expression,  the approximate relative propor- 
tions are indicated by the size of the character used. A dash means either that the ex- 
periment was not done or that the question  is not applicable. 
3-ketoacyl-CoA-thiolase in normal human fibroblasts (Fig. 
2, A-D). No significant mitochondrial localization was de- 
tected, even for AGT~ that in normal human liver is found 
to a level of ~5-10%  in the mitochondria (in individuals 
homozygous for the minor AGT allele) (34). On the other 
hand, the mutant form of AGT found in PH1 patients with 
the peroxisome-to-mitochondrion AGT mistargeting phe- 
notype (i.e., AGT  v) was localized mainly in the mitochon- 
dria with much less in the peroxisomes (Fig. 2, E  and F). 
This compares with a 90% mitochondrial and 10% peroxi- 
somal localization in livers of PH1 patients who are ho- 
mozygous for the AGTV allele (see Table III) (6, 34). 
Role of the Gly170~Arg Mutation in the 
Peroxisome-to-Mitochondrion Mistargeting of 
AGT in PHI 
AGT~ contains  two amino acid differences compared to 
AGT  ~  (i.e.,  Proll-->Leu  and  Ile340--->Met  substitutions, 
see Table  I  and  reference 34).  AGT~ contains  an  addi- 
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determine the roles of these substitutions in the peroxiso- 
mal or mitochondrial compartmentalization of AGT, arti- 
ficial AGT constructs containing all of the possible combi- 
nations of the three amino acid differences were expressed 
in normal fibroblasts (Fig. 3, A-C).  It was found that only 
when  the  Proll---~Leu  and  Gly170---~Arg  substitutions 
were present together (i.e., in AGT-lri, Fig. 3 B) was AGT 
distributed similarly to that found with AGT  v (Fig. 2 E) 
(i.e., mitochondrial and peroxisomal). In  all other cases, 
AGT was localized normally in the peroxisomes (Fig. 3, A 
and C, summarized in Table III). Most significantly, AGT- 
pri was peroxisomal (as judged by its colocalization with 
thiolase, Fig. 3, C and D), a finding that was surprising as 
had  previously  been  suggested  that  the  PHI-specific 
Glyl70---~Arg  mutation  might  contribute  to  the  peroxi- 
some-to-mitochondria mistargeting phenomenon by inter- 
fering  with  the  peroxisomal  targeting  and/or  import  of 
AGT (34, 35). 
To determine whether AGT-pri (and in fact AGT  ~) had 
actually entered the peroxisomal interior and had not just 
attached to the cytoplasmic face of the organelle, cells ex- 
pressing AGT-pri (and AGT  ~) were permeabilized differ- 
entially.  After  selective permeabilization  of the  plasma 
membrane with low concentrations of digitonin (see refer- 
ence 24), only a diffuse background labeling could be de- 
tected for AGT with no evidence of any punctate distribu- 
tion (Fig. 3 E). However, after permeabilization 0f both 
plasma  membrane  and  peroxisomal membrane  (and  all 
other cellular membranes) with Triton X-100, a punctate 
distribution was manifest in addition to the background la- 
beling (Fig. 3 F). The ability to detect punctate labeling 
only after permeabilization of the peroxisomal membrane 
indicates that AGT-pri (and AGT  ~) are imported into the 
peroxisomal interior and not just attached to the exterior 
of the organelle. 
To ascertain whether the Glyl70---~Arg mutation inter- 
fered  with  the  efficiency of  AGT  peroxisomal  import, 
Figure 3.  Intracellular  local- 
ization  of  various  artificial 
derivatives  of AGT in  nor- 
mal  human  fibroblasts.  (A) 
AGT-Igi;  (B)  AGT-lri;  (C 
and  D)  double  labeling  of 
AGT-pri  (C)  and  peroxiso- 
mal thiolase  (D);  (E) AGT- 
pri  in  cells  permeabilized 
with 25  I~g/ml digitonin; (F) 
AGT-pri in  cells permeabi- 
lized with digitonin plus Tri- 
ton X-100. 
Motley  et al. PTS1 ofAlanine/Glyoxylate  Aminotransferase  101 Figure  4.  Intracellular  localization of vari- 
ous AGTs in human fibroblasts deficient in 
either  PTS1  or  PTS2-mediated  import. 
Double labeling of AGT  (A) and peroxiso- 
mal catalase (B) in PTS2- cells. Double la- 
beling of AGT  ~ (C), AGT  ~ (E), AGT  ~ (G), 
and  AGT-pri  (/)  and  peroxisomal  thiolase 
(D, F, H, and J, respectively) in PTS1- cells. 
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determined  2.5  h  after  the  microinjection of pAGT-pri 
(and pAGT  ~) and compared with that found after the nor- 
mal incubation time of 18 h (see Materials and Methods). 
Although much more diffuse cytosolic labeling was notice- 
able after this short period of time, there was no obvious 
difference in the relative proportion of punctate labeling 
between AGT-pri and AGT  ~ (data not shown), indicating 
that  the  Glyl70---)Arg mutation did not significantly de- 
crease the efficiency of AGT peroxisomal import. 
Identification  of the Peroxisomal Import Pathway 
forAGT 
To  determine  the  specific  peroxisomal  import  pathway 
used by AGT, normal and  mutant  forms of the  protein 
were expressed in fibroblasts in which import via either 
the PTS1 or PTS2 pathways is defective (Fig. 4). Expres- 
sion of pAGT  ~ in PTS2- fibroblasts, which fail to import 
thiolase  (24), gave rise to a  punctate pattern of labeling 
that colocalized  with peroxisomal catalase (Fig, 4, A  and 
B). This indicates that the peroxisomal import of AGT  ~ 
does not involve the component of the thiolase (PTS2) im- 
port pathway that is deficient in these cells. On the other 
hand, when expressed in PTS1- fibroblasts, which fail to 
import firefly luciferase and  other PTSl-containing pro- 
teins into peroxisomes (24), neither AGT  ~ nor AGT  ~ were 
localized in a particulate fashion but were instead evenly 
dispersed throughout the cytosol (Fig. 4, C-F). This find- 
ing  suggests  that  the  peroxisomal import of AGT  ~ and 
AGTa  does involve the  component of the PTS1  import 
pathway that is deficient in these ceils. The cytosolic com- 
partmentalization  of AGT  ~ and  AGT~  in  PTS1-  fibro- 
blasts  is  very similar  to  that  of endogenously expressed 
AGT in ZS liver, except that in the case of AGTa a small 
proportion was also localized in the mitochondria in ZS 
cells (see Table III) (9). 
As expected, AGT~, when expressed in PTS1- cells, was 
localized solely within the mitochondria (Fig. 4, G and H). 
However, when AGT-pri was expressed in such cells, the 
distribution  was diffuse with no indication of mitochon- 
drial labeling (Fig. 4, I  and J). This observation confirms 
previous results obtained from isolated mitochondrial in 
vitro import studies (35) that the Glyl70---~Arg mutation 
found in some PH1 patients does not on its own directly 
affect mitochondrial import even in the absence of an ef- 
fective peroxisomal import machinery. 
Characterization  of the Peroxisomal  Targeting 
Sequence of  AGT 
After the observation that the Gly170--~Arg mutation did 
not  inhibit  AGT  peroxisomal  targeting,  and  therefore 
could not contribute to the peroxisome-to-mitochondrion 
mistargeting phenomenon by interfering with any putative 
"internal" PTSs (see reference 4), and the observation that 
AGT  was  probably  imported  into  peroxisomes  via  the 
PTS1 pathway, the role of the COOH terminus of AGT in 
peroxisomal targeting and import was investigated. When 
the  COOH-terminal  tripeptide  KKL  was  deleted  from 
normal human AGTs (i.e., AGT~-A1 and AGT~-A1), per- 
oxisomal import in  normal  fibroblasts  was  totally  abol- 
ished, as it was when the KKL of AGT  ~ was replaced by 
SEL,  DEL  or  LLL (Fig.  5,  A-D).  However, when  the 
KKL of AGT  ~ was replaced by the COOH-terminal tri- 
peptides found in the AGT of other mammalian species 
(i.e., SQL and NKL); or the prototypical PTS1 from firefly 
luciferase (i.e., SKL), or even SSL, peroxisomal targeting 
Figure  5.  Intracellular  local- 
ization of various  COOH-ter- 
minally mutated derivatives of 
AGT that fail to be imported 
into  peroxisomes  in  normal 
human  fibroblasts.  (A)  AGT- 
A1; (B) AGT-SEL; (C) AGT- 
DEL; (D) AGT-LLL. 
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ization  of  various  COOH- 
terminally  mutated  deriva- 
tives  of  AGT  that  are 
imported into peroxisomes in 
normal  fibroblasts.  Double 
labeling  of  AGT  (left  col- 
umn)  and peroxisomal thio- 
lase (center column).  Panels 
on  the  right  show  labeling 
pattern when cells expressing 
the AGT derivatives are per- 
meabilized  with  25  txg/ml 
digitonin.  (A  and  C)  AGT- 
SQL; (D and F) AGT-NKL; 
(G and/) AGT-SKL; (J and 
L)  AGT-SSL.  As  has  been 
found  previously  (24),  nu- 
clear  fluorescence  is  some- 
times  observed  after  intra- 
nuclear  microinjection  of 
expression  plasmids  (see  G 
and  /).  This finding is idio- 
syncratic and currently defies 
explanation.  However,  in 
the present study at least, nu- 
clear fluorescence was highly 
variable and unrelated to any 
particular construct. 
and import was maintained (Fig. 6, A-L).  In all cases, se- 
lective permeabilization using digitonin demonstrated that 
punctate labeling was due to import into the peroxisomal 
matrix and not adherence to the exterior of the organelle 
(Fig.  6,  C,  F,  /,  L).  Mitochondrial  labeling was  not  de- 
tected  with  any  of  the  COOH-terminal  mutants,  even 
when  AGTa-A1  (or  AGT~-A1)  was  expressed  in  PTS1- 
cells (data not shown). A  summary of the results of the in- 
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terminally mutated  as  well as  other AGT derivatives is 
shown in Table III. 
These results are compatible with the COOH-terminal 
tripeptides of human, marmoset, rabbit, rat, and cat AGTs 
all being  PTSls.  However, even though  KKL is  clearly 
necessary for the correct intracellular compartmentation 
of AGT, it appears to be unable to direct the targeting and 
import  of  another  peroxisomal  protein  (i.e.,  firefly lu- 
ciferase). Although  unmodified firefly luciferase has  al- 
ready been shown to be targeted and imported into the 
peroxisomes of normal fibroblasts (24), substitution of the 
COOH-terminal SKL by KKL in the present study abol- 
ished targeting (Fig. 7). A  similar result has been found 
previously using transfected monkey CV-1  cells  (15).  In 
addition, although the prototypical PTS1, SKL, was able 
to target the reporter protein CAT to the peroxisomes in 
the present system, KKL was unable to do so (Fig. 8). 
In  an  attempt  to  determine  whether  any  part  of the 
AGT  polypeptide  contiguous  with  the  COOH-terminal 
KKL might play a  role in its peroxisomal targeting, two 
constructs (AGT-A2 and  AGT-A3) were made in which 
the  10  or 44 amino  acids,  respectively, immediately up- 
stream of the KKL were deleted. These constructs failed 
to be targeted to peroxisomes (Fig. 9, A-D), suggesting ei- 
ther that the PTS1 of AGT extends beyond its COOH-ter- 
minal  tripeptide,  or that  the  regions  deleted provide at 
least part of the structural context within which KKL is 
able operate as a PTS1. However, despite the apparent ne- 
cessity of these internal sequences for the peroxisomal tar- 
geting  of  AGT,  neither  the  COOH-terminal  13  or  47 
amino acids (including the KKL) of AGT were able to tar- 
get the CAT-fusions CAT+AGT13 and CAT+AGT47 to 
peroxisomes (Fig. 9, E-H). It is very unlikely that the fail- 
ure of CAT+AGT47 to target to peroxisomes is due to 
any  structural  imcompatibility  between  the  CAT  and 
AGT polypeptide sequences that might lead to aggrega- 
tion  etc.,  as  a  similar  construct  (CAT+AGT47-SKL) in 
which the COOH-terminal KKL was replaced by SKL was 
imported into peroxisomes (data not shown). 
Discussion 
The observation that the peroxisomal targeting of AGq  -~ 
and  AGT~  is  completely abolished  when  expressed  in 
PTS1- fibroblasts, but is completely normal in PTS2- fi- 
broblasts, inevitably leads to the conclusion that AGT is 
targeted and imported into peroxisomes by way of at least 
one component of the PTS1 import machinery. Comple- 
mentation analysis has shown that a single gene defect is 
responsible for peroxisomal dysfunction in the AAL85AD 
(PTS1-) cell line (2). In addition, a mutation has recently 
been identified in the putative PTSl-receptor gene in this 
cell line (13) (described as cell line PBD018 in the latter 
publication). Therefore, it is likely that AGT is imported 
into peroxisomes by way of the PTS1 receptor, and, conse- 
quently, it is equally likely that the PTS of AGT is a PTS1. 
The mammalian PTS1, as currently defined, consists of a 
simple tripeptide based on the SKL motif that is only func- 
tional when placed at the COOH terminus. Even a single 
amino acid addition (15) or amidation of the et-carboxyl 
group (22) can abolish targeting. Internal SKLs or similar 
motifs that have from time to time been speculated to be 
PTSs (25) have never been proven to be so. Targeting se- 
quences, including PTSs, are usually defined as those se- 
quences that are both necessary and sufficient to direct the 
targeting of polypeptides to a particular organelle, and the 
prototypical PTS1 (i.e., SKL) certainly fulfils these general 
requirements (14). However, the data presented in this pa- 
per on the targeting of AGT suggest that either the gen- 
eral definition of targeting sequences, at least as applied to 
PTSls, is inadequate or that the currently recognized  de- 
scription of the mammalian PTS1 is incomplete. 
The finding that the import of both AGT  ~ and AGT~ 
into  peroxisomes  of  normal  human  fibroblasts  is  com- 
pletely abolished when the  COOH-terminal KKL is  de- 
leted is indicative of the necessity of this sequence for the 
protein's correct intracellular compartmentalization. How- 
ever, previous studies have already shown that KKL is not 
sufficient to target firefly luciferase either to peroxisomes 
of monkey kidney CV-1 cells (15) or to glycosomes of Try- 
panosoma brucei (38), and in the present study KKL has 
been shown to be insufficient to target firefly luciferase or 
CAT to peroxisomes in human fibroblasts. Therefore, the 
COOH-terminal  KKL of human  AGT, which has  a  2/3 
match with the prototypical PTS1 SKL, would appear to 
be able to fulfil only one of the general requirements of a 
targeting sequence (i.e., it is necessary). 
There are  at  least two possible explanations for these 
apparently contradictory findings. The first is  that  KKL 
might be able  to act as a  PTS1  only within a  particular 
structural context, the role of which might be concerned 
with the presentation of the PTS1, rather than being part 
of the PTS1 itself. The efficiency with which the PTS1 is 
Figure 7.  Intracellular  local- 
ization  of  firefly  luciferase- 
SKL (A) and luciferase-KKL 
(B) in normal  human  fibro- 
blasts. 
Motley  et al. PTSI ofAlanine/Glyoxylate  Aminotransferase  105 Figure 8.  Intracellular localization of CAT and various COOH-terminal CAT fusions in normal human fibroblasts. Double labeling of 
CAT (A), CAT-SKL (C), CAT-KKL (E), and catalase (B, D, and E, respectively), immunofluorescence  being observed by confocal la- 
ser-scanning  microscopy. 
The Journal  of Cell Biology, Volume 131, 1995  106 Figure 9.  Intracellular localization of AGT internal deletions and CAT-AGT fusions in normal human fibroblasts. Double labeling of 
AGT internal deletions AGTo~-A2  (A), AGTa-A3 (C), CAT-AGT fusions CAT+AGT13 (E), CAT+AGT47 (G), and catalase (B, D, 
F, and H, respectively). The CAT-AGT  fusions were detected using antibodies against CAT and not AGT. 
Motley et al, PTS1 ofAlanine/Glyoxylate  Aminotransferase  107 presented to the PTS1 receptor is likely to be dependent 
on many factors, including polypeptide folding and/or oli- 
gomerization. Why the  presentation of KKL should  re- 
quire a  different context to that required by SKL is un- 
known. It is also puzzling that, although the context within 
which the PTS1 of AGT is required to operate is very spe- 
cific (i.e., AGT provides the context but FFL and CAT do 
not), the PTS1 itself is very degenerate. This clearly has 
major implications for the targeting of other peroxisomal 
proteins that do not appear to possess the minimum con- 
sensus PTS1, as currently defined. If AGT, and possibly 
other peroxisomal proteins as well, do possess enabling se- 
quences not directly involved in targeting, then the classi- 
cal definition of a PTS as being both "necessary and suffi- 
cient" would appear to be no longer adequate. A perfectly 
genuine PTS1 might be able to target only one, or a lim- 
ited number of proteins to the peroxisomes. This might 
even apply to the prototypical PTS1, as previous studies 
have shown that in Saccharomyces cerevisiae a COOH-ter- 
minal SKL can direct the peroxisomal import of firefly lu- 
ciferase, whereas it is unable to do so for dihydrofolate re- 
ductase  (12).  As  far as AGT is  concerned, it is not yet 
known what part of the polypeptide provides the correct 
context, except that the sequence immediately adjacent to 
the COOH-terminal KKL (i.e., the last 47 amino acids) is 
unable to do so. 
A survey of the literature reveals a number of instances, 
especially in heterologous import systems, where COOH- 
terminal  sequences  in  peroxisomal  proteins  have  been 
shown to be necessary but not sufficient (1, 12), and some 
where they have been shown to be sufficient but not nec- 
essary (19). In the present study, AGT has been expressed 
in an homologous system, in so far as both polypeptide 
and cell line were human in origin. This situation is fre- 
quently not possible in peroxisomal import studies due to 
the interference from endogenous gene expression. In the 
present  case,  advantage has  been made  of the  fact that 
AGT is expressed in a cell-specific manner (i.e., although 
AGT is expressed at high levels in human hepatocytes, en- 
dogenous  expression  in  human  fibroblasts  is  undetect- 
able). For studies into peroxisomal protein targeting, fire- 
fly  luciferase  and  other  reporter  polypeptides,  such  as 
CAT,  are  almost  always  expressed  or  otherwise  intro- 
duced into heterologous systems (i.e., into cells from gen- 
era, classes,  phyla, or even kingdoms  different to  those 
from which the polypeptide originated). Although this ap- 
proach has shown that many aspects of the peroxisomal 
import pathway are evolutionarily conserved (16, 18), ex- 
trapolations between different heterologous systems can 
be problematic. 
A  second possible explanation of our findings, with re- 
spect to the peroxisomal targeting of AGT, is that the cur- 
rent definition of the  PTS1  is  incomplete. The PTS1  in 
some  peroxisomal  proteins  might  extend  beyond  the 
COOH-terminal tripeptide, possibly including noncontig- 
uous sequences. If the PTS1 is different in different pro- 
teins, then each protein might be expected to interact with 
the PTS1 receptor differently. For example, the putative 
non-COOH-terminal  component  of the  PTS1  of AGT 
might interact with the PTS1 receptor or an accessory pro- 
tein in a way that allosterically modifies the interaction of 
the  COOH-terminal component (i.e., KKL) with the re- 
ceptor. Such a dual interaction could also modify the al- 
lowable  degeneracy of the  COOH-terminal  part  of the 
PTS1  to include sequences  as  dissimilar  as  KKL, NKL, 
SQL, SKL, and SSL, as found in the present study. On the 
other hand, classical PTSls (i.e., SKL etc. [15, 41]) might 
bind to the PTS1 receptor with such high affinity that addi- 
tional sequences  outside  the  COOH-terminal  tripeptide 
are not necessary. 
The role of the Gly170---)Arg mutation in the AGT of 
PH1  patients  manifesting  the  peroxisome-to-mitochon- 
drion AGT mistargeting phenotype remains an enigma (6, 
34). Results obtained in the present study exclude the pos- 
sibility that it potentiates the functional efficiency of the 
MTS generated by the Proll---)Leu polymorphism by in- 
terfering with AGT peroxisomal targeting  or import.  A 
molecular explanation of its  remarkable  in  vivo-specific 
facilitating action (34, 35) will have to await the outcome 
of further study. 
We would like to thank Dr. E. Middelkoop for introducing us to the tech- 
nique of microinjection. 
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